LEADER 01511nam  2200421   450 
001 9910148707803321
005 20230803015516.0
010   $a1-62257-772-8
035   $a(CKB)3710000000922361
035   $a(MiAaPQ)EBC4743904
035   $a(EXLCZ)993710000000922361
100   $a20130312h20132013  uy|            0
101 0 $aeng
135   $aurcnu||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 00$aFDA review of drug applications /$fMorris Cooperman and Richard J. Porter, editors
210  1$aNew York :$cNova Science Publishers, Incorporated,$d[2013]
210  4$dİ2013
215   $a1 online resource (97 pages) $cillustrations
225 1 $aGovernment procedures and operations
311   $a1-62257-771-X 
320   $aIncludes bibliographical references and index.
327   $aPrescription Drug User Fee Act (PDUFA): issues for reauthorization (PDUFA V) in 2012 / Susan Thaul -- Prescription drugs: FDA has met most performance goals for reviewing applications / United States Government Accountability Office.
410  0$aGovernment procedures and operations.
606   $aPharmaceutical policy$zUnited States
615  0$aPharmaceutical policy
676   $a344.7304233
702   $aCooperman$b Morris
702   $aPorter$b Richard J.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910148707803321
996   $aFDA review of drug applications$92880615
997   $aUNINA